Canton Biologics operates an integrated manufacturing facility with full Drug Substance (DS) and Drug Product (DP) capabilities, offering over 13,000 L of bioreactor capacity and an annual output of 200+ batches. The site is GMP-compliant with NMPA, FDA, and EMA standards and has passed EU QP audit.
Equipped with 50–2000 L single-use bioreactors and multiple aseptic fill-finish lines—including vial (liquid and lyophilized), PFS, nasal/throat spray, and BFS—the facility supports development from preclinical stages to commercial production.
Capabilities cover proteins, viral vectors, and cell-based products, supported by multiple upstream platforms and extensive single-use technologies to ensure flexible and efficient manufacturing.